FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in hematological malignancies. and complete random sequence (type III). From the 154 patients, we confirmed that high ITD allelic ratio (≥.5) and allogeneic stem cell transplant treatment under CR1 are independent prognostic factors. We also presented evidence that ITD integration sites in the hinge region or beta1-sheet region are an unfavorable prognostic factor in adult AML patients with FLT3-ITD mutations. These findings may help to decipher the mechanisms of FLT3-ITD in-frame duplication events and stratify patients when considering different therapeutic combinations.
FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in hematological malignancies. FLT3 internal tandem duplication (FLT3-ITD) mutations located in juxtamembrane domain (JMD) and tyrosine kinase domain 1 (TKD1) regions account for two-thirds of all FLT3 mutations. The outcome of patients remains unsatisfactory, with low survival rates. It is not yet known whether the different mutations within the FLT3 gene are all associated with patient outcome. In addition, the cause of FLT3-ITD in-frame duplication events remains unknown. Although there are some published studies investigating the FLT3-ITD mutation and its clinical implications in Chinese acute myeloid leukemia (AML) patients, sample sizes tend to be small and detailed molecular profiles of FLT3 mutations are lacking in these studies. In our study, 227 FLT3-ITD sequences were analyzed from 227 Chinese de novo AML patients. ITD were next classified into 3 types based on molecular profiles of insertion DNA sequences: DNA complete duplication (type I), DNA partial duplication (type II) and complete random sequence (type III). From the 154 patients, we confirmed that high ITD allelic ratio (≥.5) and allogeneic stem cell transplant treatment under CR1 are independent prognostic factors. We also presented evidence that ITD integration sites in the hinge region or beta1-sheet region are an unfavorable prognostic factor in adult AML patients with FLT3-ITD mutations. These findings may help to decipher the mechanisms of FLT3-ITD in-frame duplication events and stratify patients when considering different therapeutic combinations.
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| INTRODUC TI ON
FMS-like tyrosine kinase 3 (FLT3) belongs to the class III receptor tyrosine kinase (RTK) family. FLT3 mutations have been found in 15%-35% of acute myeloid leukemia (AML) patients, making FLT3 one of the most frequently mutated genes in hematological malignancies.
1,2 FLT3 mutations consist of 2 major types: FLT3 internal tandem duplications (FLT3-ITD) and point mutations within the activation loop of the second tyrosine kinase domain (FLT3-TKD).
2,3
FLT3-ITD mutations located in juxtamembrane domain (JMD) and TKD1 regions account for two-thirds of all FLT3 mutations.
Meanwhile, FLT3-ITD vary in mutant/wt ratio, number of clones and ITD insertion sites, which range from 3 to more than 400 base pairs. [4] [5] [6] [7] However, the cause of FLT3-ITD in-frame duplication events remains unknown.
FLT3-ITD mutation has been indicated as an independent variable in most of the retrospective data that confer a poor prognosis in AML. [8] [9] [10] Furthermore, previous studies observed a prognostic role for the mutant/wt ratio, size, number of clones, and location of the ITD. Multiple retrospective studies consistently suggest a high mutant/wt ratio to be an independent prognostic factor. has a favorable prognosis, and allo-HSCT in CR1 is not actively recommended. 18 In contrast, the guidelines of the National
Comprehensive Cancer Network (NCCN) classify the FLT3-ITD gene mutation as a poor prognostic factor. Conflicting results are also reported in the literature about the role of FLT3-ITD gene mutation in prognosis. [19] [20] [21] [22] Thus, further studies are required to clarify these issues. Although there are some published studies investigating FLT3-ITD mutation and its clinical implications in Chinese AML patients, the sample sizes tend to be small and detailed molecular profiles of FLT3 mutations are lacking in these studies.
In the present study, we analyzed 227 ITD sequences from 227 AML patients and classified them into different types. In addition, from the 154 selected patients, we examined the insertion sites of ITD, the mutant/wt ratio of ITD, cytogenetic risk types and other related gene mutations, and correlated these variables with clinical outcome. 
| ME THODS

| Patients and treatment
| Genescan analysis
For Genescan analysis, an ABI 3730 automated sequencer was used.
PCR setup and PCR conditions were the same as described above except that PCR primer "FLT3-F" was labeled with HEX and amplified for 25 cycles here. For allele ratio calculation, we used the value of mutant/wt ratio ( Figure S2 ), while in the case of 2 or more different FLT3-ITD mutations presenting in 1 individual patient, the allelic loads were added up. When cross effects occured between variables, landmark analyses were performed according to a landmark point at 6 months, with the hazard ratio (HR) calculated separately for events that occurred up to 6 months after study initiation and events that occurred between 6 months and the end of the follow-up period.
| Statistical analysis
We then performed a test for the interaction between variable and time (first 6 months vs subsequent period). The last observation was 19 July 2016.
F I G U R E 1 Molecular characteristics and classification of FLT3-ITD. All 227 ITD insertion base sequences were divided into 3 types or 5 subtypes based on their molecular profiles. Based on the functional regions from Griffith and Kayser, ITD were categorized into 8 subgroups.
The black color regions stand for duplicated amino acid sequences, the blue color regions stand for random amino acid sequences or amino acids translated by transcripted partial intron sequences. ITD, internal tandem duplication 3 | RE SULTS
| Molecular characteristics and classification of FLT3-internal tandem duplication
We screened 1101 de novo AML patients for the presence of FLT3- 
| Clinical significance of FLT3-internal tandem duplication mutant level
The clinical data of the 154 de novo adult AML patients (18-65 years, excluding APL) with FLT3-ITD mutations are given in Table 1 were included in the analysis for DFS. The estimated DFS rates at 3 years for high and low mutant level groups were 18.7% vs 28.7%, respectively (P = .035) ( Figure 2B ).
| Clinical significance of FLT3-internal tandem duplication insertion site
Internal tandem duplication insertion sites were divided into JMD and TKD1 subgroups to evaluate the impact of the FLT3-ITD insertion site on clinical outcome. JMD subgroup patients (29.5%) achieved a better OS rate at 3 years compared to the TKD1 subgroup (16.6%) (P = .038) ( Figure 3A ) (Table S2 ). The difference of DFS rate at 3 years for JMD and TKD1 subgroups was not statistically significant (P = .130) ( Figure 3B ). Because the DFS curves crossed, we selected 6 months as a cut-off point and ran landmark analysis. From the results, JMD subgroup patients (66.0%) achieved a better DFS rate within 6 months compared to the TKD1 subgroup (43.8%) (P = .006). However, after 6 months, the difference of DFS rate for JMD and TKD1 subgroups was not statistically significant (P = .430) ( Figure 3C ).
Then, based on functional region, ITD insertion sites were divided into 4 subgroups: JM-S or JM-Z, hinge region, beta1-sheet, and other TKD1. The results showed that patients with ITD insertion sites in the hinge region or the beta1-sheet region had a significantly worse OS rate at 3 years than patients with ITD in other regions (P = .005), with estimated OS rates of 16.4% and 32.4%, respectively ( Figure 3D ). Although patients with ITD insertion sites in the hinge region or the beta1-sheet region had an inferior DFS rate at 3 years compared with patients with ITD in other regions (19.2% vs 26.6%); this difference is not statistically significant (P = .140) ( Figure 3E ). From the landmark analysis, within 6 months, hinge region or beta1-sheet subgroup patients (46.50%) achieved a worse DFS rate compared to the other region subgroup (67.2%) (P = .016), and after 6 months, the difference was not statistically significant (P = .601) ( Figure 3F ).
| Efficacy of allogeneic stem cell transplant in FLT3-internal tandem duplication mutated acute myeloid leukemia
To determine the efficacy of Allo-SCT in patients with FLT3-ITD, patients were divided into Allo-SCT under CR1 (N = 45) and others subgroups (N = 109). The results revealed that patients with Allo-SCT under CR1 achieved significantly better OS and DFS rates at 3 years compared to the others subgroup (P < .001; P < .001), with the estimated OS and DFS 52.1% vs 14.2% and 44.2% vs 12.0%, respectively ( Figure 4A , B).
| Efficacy of NPM1 mutation on FLT3-internal tandem duplication mutated acute myeloid leukemia
To analyze the prognosis of NPM1-mutated AML with FLT3-ITD low AR, patients were divided into 3 subgroups according to the 2017 
F I G U R E 2 Survival analysis for FLT3-ITD-mutated acute myeloid leukemia (AML) according to mutant/wt ratio. A, Estimated 3 y overall
survival (OS) rate for patients with mutant/wt ratio >.5 vs <.5; the group differences were examined using a log-rank test. B, Estimated 3 y disease-free survival (DFS) rate for patients with mutant/wt ratio >.5 vs <.5; the group differences were examined using a log-rank test | 3987
To further analyze the effect of Allo-SCT under CR1 for the NPM1-mutated AML patients with FLT3-ITD low AR, 67 patients with FLT3-ITD low AR were picked out, 33 of which were mutated on NPM1 gene. From the analysis, NPM1-mutated patients who achieved Allo-SCT under CR1 had better DFS rates (53.3% vs 10.9%) at 3 years (P = .019); however, the difference of OS rates (53.3% vs 13.6%) was not statistically significant (P = .074) ( Figure 5C, D) . The NPM1 WT patients achieved better OS (55.1% vs 27.3%) and DFS (56.3% vs 11.7%) than other patients (P = .044, P = .008) ( Figure 5E , F).
| Prognostic factors
Prognostic factors were evaluated for OS and DFS using Cox regression models. In the univariate model, age was another significant factor for worse OS rate with HR of 1.02 (P = .027). High cytogenetic risk was a significant factor for worse OS rate with an HR of 4.17 (P = .009), but it was not statistically significant for DFS rate (P = .064). The presence of NPM1 mutations or CEBPA mutations or DNMT3A, Sex, and LogWBC were not associated with clinical outcome in this univariate model (Table S3 ). In the multivariate model, F I G U R E 3 Survival analysis for FLT3-ITD-mutated acute myeloid leukemia (AML) according to insertion sites. A, Estimated 3 y overall survival (OS) rate for FLT3-ITD insertion sites within JMD vs TKD1 region; the group differences were examined using a log-rank test. B, Estimated 3 y disease-free survival (DFS) rate for FLT3-ITD insertion sites within JMD vs TKD1 region; group differences were examined using a log-rank test. C, Estimated 6 month and 6 month-3 y DFS rate for FLT3-ITD insertion sites within JMD vs TKD1 region; the group differences were examined by landmark analysis. D, Estimated 3 y OS rate for FLT3-ITD insertion sites within the beta1-sheet or hinge region vs all other insertion sites; the group differences were examined using a log-rank test. E, Estimated 3 y DFS rate for FLT3-ITD insertion sites within the beta1-sheet or hinge region vs all other insertion sites; the group differences were examined using a log-rank test. F, Estimated 6 month and 6 month-3 y DFS rate for FLT3-ITD insertion sites within the beta1-sheet or hinge region vs all other insertion sites, the group differences were examined by landmark analysis. ITD, internal tandem duplication
Efficacy of allogeneic stem cell transplant (Allo-SCT) for FLT3-ITD-Hmutated acute myeloid leukemia (AML) patients. A, Overall survival (OS) rate for patients received Allo-SCT under first complete remission (CR1) and others. The group differences were examined using a log-rank test. B, Disease-free survival (DFS) rate for received Allo-SCT under CR1 and others. The group differences were examined using a log-rank test. ITD, internal tandem duplication
a high FLT3-ITD mutant/wt ratio and high cytogenetic risk group were still independent prognostic factors for an inferior outcome for OS and for DFS in different models (P < .05). Furthermore, Allo-SCT under CR1 was an independent prognostic factor for better OS and DFS rates in different models (P < .05). For OS and DFS rates, FLT3-ITD located in beta1-sheet or hinge regions was worse than in other regions; however, the differences were not significant (P > .05, P > .05) ( Table 2 ).
| D ISCUSS I ON
As most frequently mutated gene in AML, FLT3 and its activated mutations have been systematically studied over the past 20 years.
Studies related to FLT3-ITD are focused on the cause of these duplication events, signaling pathways involved in pathogenesis, molecular characterization and correlation with clinical outcome and the potential as a drug target. In the present study, we analyzed 227 ITD F I G U R E 5 Efficacy of NPM1 mutation on FLT3-ITD-mutated acute myeloid leukemia (AML). A, Overall survival (OS) rate for patients in low-risk subgroup (NPM1 MUT with FLT3-ITD low AR), medium risk subgroup (NPM1 WT with FLT3-ITD low AR, or NPM1 MUT with FLT3-ITD high AR), and high-risk subgroup (NPM1 WT with FLT3-ITD high AR). The group differences were examined using a log-rank test. B, Disease-free survival (DFS) rate for patients in low risk subgroup (NPM1 MUT with FLT3-ITD low AR), medium risk subgroup (NPM1 WT with FLT3-ITD low AR, or NPM1 MUT with FLT3-ITD high AR), and high risk subgroup (NPM1 WT with FLT3-ITD high AR). The group differences were examined using a log-rank test. C, OS rate for NPM1-mutated patients who achieved allogeneic stem cell transplant (Allo-SCT) under CR1 and others. The group differences were examined using a log-rank test. D, DFS rate for NPM1-mutated patients who achieved Allo-SCT under CR1 and others. The group differences were examined using a log-rank test. E, OS rate for NPM1 WT patients who achieved Allo-SCT under CR1 and others. The group differences were examined using a log-rank test. F, DFS rate for NPM1 WT patients who achieved Allo-SCT under CR1 and others. The group differences were examined using a log-rank test. ITD, internal tandem duplication TA B L E 2 Multivariate Cox regression models about association between variables and survival
Overall survival PFS time (≤6 months) PFS time (>6 months)
P for interaction
Hazard ratio (95%CI) P-value
Hazard ratio (95%CI) P-value
Model 1
Mutation/wt (≥.5 vs <. sequences from 227 AML patients and classified them into different types. In addition, from the 154 patients, we confirmed that high mutant/wt ratio and Allo-SCT treatment under CR1 were independent prognostic factors. Moreover, we identified that ITD integration sites in the hinge region or beta1-sheet region appear to be an unfavorable prognostic factor in adult AML patients with FLT3-ITD mutations.
The cause of FLT3-ITD in-frame duplication events remains unknown. To decipher the mechanisms, it is important to characterize the ITD molecular profiles, such as the duplication pattern, the size and the insertion site). In this paper, we found that when ITD contained the whole intron in genomic DNA, the whole intron was removed after transcription, which was confirmed by PCR and sequencing detection.
However, when ITD contains part of the intron, the partial intron would remain during DNA transcription ( Figure S3 ). Although some of study groups also used cDNA as a detection template, The molecular characteristics of ITD, such as mutant/wt ratio and insertion sites, are considered to correlate with clinical outcome in previous reports. In a large retrospective study of adult AML patients with FLT3-ITD mutations, patients with a high mutant/wt ratio had significantly shorter OS and DFS. 4 Subsequent retrospective studies of pediatric de novo AML patients showed worse prognosis with mutant/wt ratio higher than .4 or .51. 12, 13, 28 In this paper, we confirmed that patients with mutant/wt ratio of higher than .5
had significantly worse OS and DFS based on multivariate models.
Therefore, the mutant/wt ratio as an independent variable is recommended for use in clinical trials for adult AML patients in the future. FLT3-ITD-mutated AML patients are often referred for allo-SCT in first complete remission, which is becoming the preferred therapeutic option. 30 From our data, Allo-SCT under the CR1 subgroup achieved significant better OS and DFS survival and this approach can be considered as an independent favorable factor in multivariate models. Mutations of NPM1 and CEBPA are generally associated with a trend for better clinical outcomes; however, most studies indicate that this benefit is lost in the presence of FLT3-ITD. [31] [32] [33] [34] In our study, the presence of NPM1 or CEBPA mutation is not significant for OS and DFS rates. For AML cases, both with NPM1 mutant and FLT3-ITD low AR, although DFS can be improved by Allo-SCT under CR1
(P = .014), these advantages did not translate into eventual survival benefits (P = .074), which may be due to higher transplantation- Food and Drug administration approved midostaurin for the treatment of FLT3-mutated adult AML patients. 36, 37 In our study, FLT3
inhibitors were not recommended to the patients, so we did not analyze the effects of FLT3 inhibitors on FLT3-ITD mutation-positive patients.
In summary, the results of this study demonstrate that ITD can be classified into 3 types: DNA complete duplication (type I), DNA partial duplication (type II) and complete random sequence (type III). High ITD allelic ratio (≥.5) and Allo-SCT treatment under CR1 are independent prognostic factors. ITD integration sites in the hinge region or beta1-sheet region are an unfavorable prognostic factor in adult AML patients with FLT3-ITD mutations. Taken together, these findings may help to decipher the mechanisms of FLT3-ITD in-frame duplication events and stratify patients when considering different therapeutic combinations. 
| E TH I C S
